# Yuri Rukazenkov

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yuri-rukazenkov/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,567 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 30 |
| i10-index | 46 |
| Last Known Institution | AstraZeneca (United Kingdom) |
| OpenAlex ID | https://openalex.org/A5020813615 |
| Works | 91 |

## Researcher papers

- [Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-untreated-i-egfr-i-mutated-advanced-non-small-cell-lung-cancer/)
- [Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-untreated-i-egfr-i-mutated-advanced-nsclc/)
- [Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-resected-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)](https://scholariq.org/papers/biomarker-analyses-and-final-overall-survival-results-from-a-phase-iii/)
- [Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/osimertinib-with-or-without-chemotherapy-in-i-egfr-i-mutated-advanced-nsclc/)
- [Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-resected-i-egfr-i-mutated-nsclc/)
- [Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-as-first-line-treatment-of-i-egfr-i-mutation-positive-advanced-non/)
- [Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study](https://scholariq.org/papers/mechanisms-of-acquired-resistance-to-first-line-osimertinib-preliminary-data/)
- [Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-untreated-egfr-mutated-advanced-nsclc/)
- [Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis](https://scholariq.org/papers/osimertinib-versus-platinum-pemetrexed-for-patients-with-egfr-t790m-advanced/)
- [Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses](https://scholariq.org/papers/gefitinib-plus-chemotherapy-versus-chemotherapy-in-epidermal-growth-factor/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)

## Researcher university

- [AstraZeneca (United Kingdom)](https://scholariq.org/institutions/astrazeneca-united-kingdom/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.